查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1591734

抗生素抗性市场:现状分析与预测(2024年～2032年)

Antibiotic Resistance Market: Current Analysis and Forecast (2024-2032)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 146 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

由于研发活动的增加，抗生素抗药性市场预计将以 5.4% 左右的速度稳定成长。例如，2022年11月启动了抗菌素抗药性多利益相关者伙伴关係平台，以应对全球日益增长的抗菌素抗药性威胁和影响。联合国粮食及农业组织（FAO）、联合国环境规划署（UNEP）、世界卫生组织（WHO）和世界动物卫生组织（WOAH）加入了这项名为四方会议的倡议，以强调抗生素抗药性对人类、动物、植物、生态系统和生计的威胁。此外，抗生素抗药性感染病例的增加和抗生素研发活动的投资增加正在推动抗生素抗药性市场的发展。

依疾病类型，市场分为泌尿道感染、腹腔内感染、血流感染、艰难梭菌感染等。预计泌尿道感染 (UTI) 领域将在 2023 年占据市场的大部分占有率，这是由于 UTI 的发病率不断增加，尤其是在女性、老年人和患有慢性疾病的人群中。随着大肠桿菌等抗生素抗药性菌株的出现频率不断增加，传统治疗方法变得越来越无效，新型抗生素和其他治疗方法的市场正在蓬勃发展。由于这些感染对于许多医疗保健提供者来说难以管理，因此他们更加重视开发特定的治疗、诊断和预防方法。此外，人们对抗生素抗药性后果的认识不断提高，正在推动泌尿结石的治疗的努力和资金投入。在该领域，需要开发有效的治疗方法并加强控制措施，以对抗抗生素抗药性细菌的增加，特别是在泌尿结石中，并期待利益相关者做出积极的努力。

依病原体类型，市场分为鲍曼不动桿菌、绿脓桿菌、金黄色葡萄球菌、肺炎链球菌和其他。预计金黄色葡萄球菌部分将在预测期内显着增长，因为耐甲氧西林金黄色葡萄球菌 (MRSA) 和甲氧西林敏感菌株引起的感染正在对其他类别的抗生素产生抗药性。金黄色葡萄球菌是一种引起医院相关和社区获得性皮肤感染、肺炎、菌血症和其他感染的病原体，因此需要有效的治疗。新的抗药性细菌的出现要求製药公司开发针对这些抗药性细菌的新抗生素，以及新的治疗方法，包括单株抗体和噬菌体疗法。因此，预计在预测期内，金黄色葡萄球菌将在病原体类型中呈现显着的成长率。

依药物类别，市场分为噁唑烷酮类、脂糖肽类、四环素类及其他类。由于多重抗药性革兰氏阳性菌感染（尤其是抗甲氧西林金黄色葡萄球菌 (MRSA) 和耐万古霉素肠球菌 (VRE)）的增加，预计噁唑烷酮类药物在预测期内将显着增长。在噁唑烷酮类抗生素中，利奈唑胺和特地唑胺具有抑制细菌蛋白质合成的新途径，使其成为治疗这些难以治疗的感染的有价值的治疗药物。传统抗生素抗药性的上升促使噁唑烷酮类抗生素等新一代抗生素进入全球市场。此外，噁唑烷酮抗生素在临床环境中的使用日益增多以及不断努力开发噁唑烷酮抗生素新化合物市场也在推动这一市场的发展。噁唑烷酮市场有可能使用户能够获得针对抗药性感染的有效治疗，从而在治疗医疗机构的抗生素抗药性和最大限度改善患者健康方面发挥重要作用。因此，预计预测期内按药物类别划分的噁唑烷酮将出现显着增长。

为了更了解抗生素抗药性的市场采用情况，根据北美（美国、加拿大和北美其他地区）、欧洲（德国、英国、法国、西班牙、义大利和欧洲其他地区）、亚太地区（中国、日本、印度和亚太地区其他地区）和世界其他地区的全球存在情况对市场进行了分析。到 2023 年，北美将占据大部分市场占有率。影响北美抗生素抗药性市场成长的趋势是市场成长率以及医疗保健提供者和全体民众对抗生素抗药性作为主要威胁的认识。该地区强大的卫生系统促进了创新抗生素和其他技术和诊断工具的开发，以便及早发现和识别抗药性菌株。此外，美国政府启动的 "应对抗生素抗药性国家行动计画" 也促使公共卫生机构、製药公司和学术机构之间的资金投入增加。医疗机构高抗生素管理计画也正在加强寻找对抗抗药性细菌的方法。例如，开发新型抗感染疗法的先驱企业Entasis，以及在重症监护和医院环境药物商业化方面拥有良好业绩记录的拉霍亚製药公司（La Jolla）。 Innoviva 于 2022 年完成了对 Entasis 和 La Jolla 的收购。因此，北美将在 2023 年占据很大占有率。

在市场上营运的主要公司包括Pfizer Inc.; Orchid Chemicals & Pharmaceuticals Limited; Melinta Therapeutics, LLC; Innoviva Specialty Therapeutics; Basilea Pharmaceutica Ltd; Wockhardt Limited; Paratek Pharmaceuticals, Inc.; Seres Therapeutics, Inc.; Cipla; Merck & Co. Inc.处于。

目录

第1章 市场简介

  • 市场定义
  • 主要目的
  • 相关利益者
  • 限制事项

第2章 调查手法或前提条件

  • 调查流程
  • 调查手法
  • 受访者简介

第3章 摘要整理

  • 产业摘要
  • 各市场区隔预测
    • 市场成长的强度
  • 地区展望

第4章 市场动态

  • 促进因素
  • 机会
  • 阻碍因素
  • 趋势
  • PESTEL分析
  • 需求面分析
  • 供给方面分析
    • 合併和收购
    • 投资Scenario
    • 产业考察:大Start-Ups企业及其独特策略

第5章 价格分析

  • 各地区价格分析
  • 价格的影响因素

第6章 全球抗生素抗性市场收益 , 2022-2032年

第7章 市场洞察:各疾病类型

  • 泌尿道感染
  • 腹腔内感染疾病
  • 血流感染疾病
  • 难辨梭状芽孢桿菌传染病
  • 其他

第8章 市场洞察:病原体类别

  • 鲍氏静止桿菌
  • 绿色脓菌
  • 黄色葡萄球菌
  • 肺炎球菌
  • 其他

第9章 市场洞察:各类药物

  • Oxazolidinone
  • ripogurikopepuchido
  • 四环霉素
  • 其他

第10章 市场洞察:各地区

  • 北美
    • 美国
    • 加拿大
    • 其他北美地区
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 全球其他地区

第11章 价值链分析

  • 市场参与企业一览

第12章 竞争情形

  • 竞争仪表板
  • 竞争市场定位分析
  • 波特的五力分析

第13章 企业简介

  • Pfizer Inc.
    • Company Overview
    • Key Financials
    • SWOT Analysis
    • Product Portfolio
    • Recent Developments
  • Orchid Chemicals & Pharmaceuticals Limited
  • Melinta Therapeutics, LLC
  • Innoviva Specialty Therapeutics
  • Basilea Pharmaceutica Ltd
  • Wockhardt Limited
  • Paratek Pharmaceuticals, Inc.
  • Seres Therapeutics, Inc.
  • Cipla
  • Merck & Co. Inc.

第14章 缩写与前提条件

第15章 附录

简介目录
Product Code: UMHE213048

Antimicrobial resistance is a very sensitive and evolving threat within the healthcare market and is indicated by the emergence of multidrug-resistant organisms, to which standard antibiotics are ineffective. These increased rates have made treatment failures become more common, lengths of stay rise, and costs skyrocket, all of which have created the need for new approaches that will address the issues. Industry is keen on investing in the development of new antibiotics and other therapies, and in diagnostics tools because of the high threat level of resistant infections in patients. Other opportunities are related to the geographical areas of diagnostics advances and international partnerships that call for an active strategy to fight antibiotic resistance. In conclusion, there is great potential within the market as key players are aware that increased awareness for practical solutions to reducing the burden of antibiotic resistance on the population is needed.

The Antibiotic Resistance Market is expected to grow at a steady rate of around 5.4% owing to the rising research & development activities. For instance, in November 2022, the Antimicrobial Resistance Multi-Stakeholder Partnership Platform was launched to ensure the growing threats and impacts of antimicrobial resistance are addressed globally. The Food and Agriculture Organization of the United Nations (FAO), the United Nations Environment Programme (UNEP), the World Health Organization (WHO), and the World Organization for Animal Health (WOAH), known as the Quadripartite are joining forces on this initiative to underscore the threat antimicrobial resistance presents to humans, animals, plants, ecosystems, and livelihoods. Moreover, increasing cases of antibiotic-resistant infections and increasing investment in antibiotic research and development activities boost the antibiotic resistance market.

Based on the disease type, the market is segmented into urinary tract infections, intra-abdominal infections, bloodstream infections, clostridium difficile infections, and others. The urinary tract infections (UTIs) segment held a significant share of the market in the year 2023 owing to increased incidence of UTIs especially among females, elder people, and those with chronic diseases. As the frequency of antibiotic-resistant strains like Escherichia coli rises, traditional treatments are becoming less effective and the market for new antibiotics as well as other forms of therapy is growing rapidly. Since these infections are difficult to manage by most healthcare providers, more focus is being placed on the development of specific treatments, diagnostics, and preventive measures. Furthermore, an increased realization of antibiotic resistance consequences has boosted efforts and funding towards UTI-tailored treatments. This segment is expected to see a lot of activities from the stakeholders as there is a need to come up with effective treatment for the condition and come up with intensified management measures towards combating the increased cases of resistance in antibiotic use; especially in UTIs.

Based on the pathogen type, the market is segmented into Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Streptococcus pneumoniae, and others. The Staphylococcus aureus segment is expected to experience significant growth in the forecast period owing to infections by methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive strains, which are becoming resistant to other antibiotic classes. S. aureus is a pathogen that is recognized to cause diverse healthcare-associated and community-acquired skin infections, pneumonia, bacteremia, and other infections that urge the need for effective treatment. The new form of resistance requires the drug companies to develop new antibiotics targeting resistant bacteria, and new treatments including monoclonal antibodies and bacteriophage therapies. Thus, the Staphylococcus aureus segment is expected to grow at a significant rate in the forecast period among the pathogen type.

Based on the drug class, the market is segmented into oxazolidinones, lipoglycopeptides, tetracyclines, and others. The oxazolidinones segment is expected to experience significant growth in the forecast period owing to rising instances of multidrug-resistant Gram-positive infections especially, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE). Among the oxazolidinones, linezolid and tedizolid have become valuable therapeutic agents for managing these hard-to-treat infections owing to the new pathway through which bacterial protein synthesis is blocked. Due to the increased resistance to conventional antibiotics, the global market for new-generation antibiotics such as oxazolidinones is being introduced. In addition, the increased number of applications of these agents in clinical settings together with continuous efforts into the development of new oxazolidinone compounds also put thrust on this market. The oxazolidinones market has the potential to ensure that users get effective treatments for resistant infections and it thus plays an essential role in treating antibiotic resistance and maximizing patient health in healthcare organizations. Thus, the oxazolidinones segment is expected to grow at a significant rate in the forecast period among the drug class.

For a better understanding of the market adoption of antibiotic resistance, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America held the majority share of the market in the year 2023. The trends influencing the antibiotic resistance market growth in North America are the growing rate of the market and the recognition of antibiotic resistance as a significant threat among healthcare providers and the overall population. The strong health system of the region enables the development of innovative antibiotics and other technologies and diagnostic tools that strive to address and identify resistant strains in the early stages. Further, the launch of the National Action Plan for Combating Antibiotic-Resistant Bacteria by the U.S government increased funding between public health entities, pharmaceuticals, and academic institutions. Healthcare facility-high antibiotic stewardship programs also contribute towards increasing efforts to find ways to counter resistance. For instance, Entasis, a pioneer in the development of novel, anti-infective therapies, and La Jolla Pharmaceutical Company (La Jolla), with proven capabilities in commercializing medicines in critical care and hospital settings. Innoviva completed the acquisitions of Entasis and La Jolla in 2022. Thus, amongst areas, North America held a significant share of the market in the year 2023.

Some of the major players operating in the market include Pfizer Inc.; Orchid Chemicals & Pharmaceuticals Limited; Melinta Therapeutics, LLC; Innoviva Specialty Therapeutics; Basilea Pharmaceutica Ltd; Wockhardt Limited; Paratek Pharmaceuticals, Inc.; Seres Therapeutics, Inc.; Cipla; Merck & Co. Inc.

TABLE OF CONTENTS

1.MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2.RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Antibiotic Resistance Market
  • 2.2. Research Methodology of the Antibiotic Resistance Market
  • 2.3. Respondent Profile

3.EXECUTIVE SUMMARY

  • 3.1. Industry Synopsis
  • 3.2. Segmental Outlook
    • 3.2.1. Market Growth Intensity
  • 3.3. Regional Outlook

4.MARKET DYNAMICS

  • 4.1. Drivers
  • 4.2. Opportunity
  • 4.3. Restraints
  • 4.4. Trends
  • 4.5. PESTEL Analysis
  • 4.6. Demand Side Analysis
  • 4.7. Supply Side Analysis
    • 4.7.1. Merger & Acquisition
    • 4.7.2. Investment Scenario
    • 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.PRICING ANALYSIS

  • 5.1. Regional Pricing Analysis
  • 5.2. Price Influencing Factors

6.GLOBAL ANTIBIOTIC RESISTANCE MARKET REVENUE (USD BN), 2022-2032F

7.MARKET INSIGHTS BY DISEASE TYPE

  • 7.1. Urinary Tract Infection
  • 7.2. Intra-Abdominal Infections
  • 7.3. Blood Stream Infections
  • 7.4. Clostridium Difficile Infections
  • 7.5. Others

8.MARKET INSIGHTS BY PATHOGEN TYPE

  • 8.1. Acinetobacter Baumannii
  • 8.2. Pseudomonas Aeruginosa
  • 8.3. Staphylococcus Aureus
  • 8.4. Streptococcus Pneumoniae
  • 8.5. Others

9.MARKET INSIGHTS BY DRUG CLASS

  • 9.1. Oxazolidinones
  • 9.2. Lipoglycopeptides
  • 9.3. Tetracyclines
  • 9.4. Others

10.MARKET INSIGHTS BY REGION

  • 10.1. North America
    • 10.1.1. U.S.
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. U.K.
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Rest of Asia-Pacific
  • 10.4. Rest of World

11.VALUE CHAIN ANALYSIS

  • 11.1. List of Market Participants

12.COMPETITIVE LANDSCAPE

  • 12.1. Competition Dashboard
  • 12.2. Competitor Market Positioning Analysis
  • 12.3. Porter Five Forces Analysis

13.COMPANY PROFILES

  • 13.1. Pfizer Inc.
    • 13.1.1. Company Overview
    • 13.1.2. Key Financials
    • 13.1.3. SWOT Analysis
    • 13.1.4. Product Portfolio
    • 13.1.5. Recent Developments
  • 13.2. Orchid Chemicals & Pharmaceuticals Limited
  • 13.3. Melinta Therapeutics, LLC
  • 13.4. Innoviva Specialty Therapeutics
  • 13.5. Basilea Pharmaceutica Ltd
  • 13.6. Wockhardt Limited
  • 13.7. Paratek Pharmaceuticals, Inc.
  • 13.8. Seres Therapeutics, Inc.
  • 13.9. Cipla
  • 13.10. Merck & Co. Inc.

14.ACRONYMS & ASSUMPTION

15.ANNEXURE